ClinicalTrials.gg

Program

FB102

A development code. Also written as “FB102 Single dose - Part A”, “FB102 Multiple doses - Part B” and “FB102 Multiple doses - Part C”.

Its studies are mostly in Vitiligo · Alopecia Areata · Celiac Disease, led by argenx.

Furthest: phase 2, since May 13, 20254 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenx44 open or runningphase 2since May 13, 2025Mar 11, 2025Dec 31, 2026phase 1 · NCT06905873

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2025First study: phase 1 study in VitiligoFirst studyNCT06905873 · 64 enrolled · Australia, New Zealand
  2. May 13, 2025Phase 2 study in Celiac DiseaseNCT06982963 · 100 planned · Australia
  3. Sep 25, 2025Phase 1 study in Alopecia AreataNCT07205159 · 32 planned · Australia, New Zealand
  4. May 28, 2026Phase 1 study in Healthy VolunteerNCT07623057 · 64 planned · Australia

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in VitiligoNCT06905873
  2. Feb 2027Primary completion: phase 1 study in Healthy VolunteerNCT07623057
  3. Feb 28, 2027Primary completion: phase 2 study in Celiac DiseaseNCT06982963
  4. Mar 10, 2027Primary completion: phase 1 study in Alopecia AreataNCT07205159

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623057Healthy Volunteer · Australia1RecruitingFeb 202764
NCT07205159Alopecia Areata · Australia, New Zealand1RecruitingMar 10, 202732
NCT06982963Celiac Disease · Australia2RecruitingFeb 28, 2027100
NCT06905873Vitiligo · Australia, New Zealand1Active, not recruitingDec 31, 202664

How it is read

Names in the registry

  • “FB102”, 3 entries
  • “FB102 Single dose - Part A”, 1 entry
  • “FB102 Multiple doses - Part B”, 1 entry
  • “FB102 Multiple doses - Part C”, 1 entry

Codes read as this program: FB102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.